BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2006
Business Overview: BioCryst is a biopharmaceutical company engaged in the research and development of drug candidates, primarily focusing on enzyme targets for oncology and infectious diseases. The company has no commercial product sales and relies on collaboration agreements, license fees, and milestone payments for revenue.

Key Financial Metrics

Note: Revenue consists primarily of collaborative and other research and development fees. The company has no debt listed on the balance sheet.

Material Changes vs. Prior Period

• Revenue Surge: Collaborative revenue increased to $2.33 million for the six months ended June 30, 2006, compared to $99,000 in the prior year. This is driven by the recognition of upfront payments from the Mundipharma collaboration (began Feb 2006) and reimbursement of clinical expenses.
• Expense Growth: Total expenses rose 86% to $22.1 million. Research and Development (R&D) expenses increased 84.3% to $19.2 million due to clinical trials for Fodosine and peramivir, and manufacturing validation. General and Administrative (G&A) expenses increased 102.3% to $2.9 million, largely due to the adoption of FAS 123R (stock-based compensation) and increased personnel.
• Stock-Based Compensation: The company adopted FAS 123R effective Jan 1, 2006, recognizing $1.18 million in stock-based compensation expense for the first six months of 2006. No such expense was recognized for employees in the comparable 2005 period.
• Liquidity Improvement: Total liquid assets (cash and securities) increased from $60 million at year-end 2005 to $74.7 million at June 30, 2006, primarily due to $31.8 million in net cash received from collaborations (Roche and Mundipharma).

Outlook, Risks, and Management Commentary

• Cash Burn Rate: The average monthly cash burn was approximately $3.2 million in the first half of 2006. Management expects this to increase significantly in the second half of 2006, potentially exceeding $5 million per month, due to expanded clinical trials for peramivir and Fodosine.
• Collaboration Milestones:
  • Roche: Received $30 million upfront (recorded as receivable in 2005, collected Jan 2006). Roche assumes development costs for BCX-4208.
  • Mundipharma: Received $10 million upfront. Mundipharma reimburses 50% of clinical costs for Fodosine (up to $10 million). Revenue is deferred over the patent life (through 2017).
  • Green Cross: New collaboration announced June 2006; revenue recognition expected to begin August 2006.
• Regulatory Progress: Received a Special Protocol Assessment (SPA) letter from the FDA for a pivotal trial of Fodosine. Submitted a proposal to the Department of Health and Human Services (HHS) for funding of peramivir (antiviral) under a Request for Proposal (RFP).
• Risks: The company requires additional capital to complete development. Failure to secure funding (via equity, debt, or collaborations) could force delays or elimination of R&D programs. There is no guarantee of HHS funding or successful clinical trial outcomes.

Investor Verification Checklist

• Cash Runway: Verify if the projected $5 million monthly burn rate is sustainable given the $74.7 million cash position and the uncertainty of HHS funding.
• Revenue Recognition: Confirm the timeline for recognizing the deferred revenue from Roche (17 years) and Mundipharma (12 years) and the impact on future earnings.
• Clinical Trial Costs: Monitor the actual costs of the pivotal Fodosine trial and peramivir Phase II trials against the budget, as these drive the increased cash burn.
• Stock-Based Compensation: Review the remaining unrecognized compensation cost ($10 million) and its impact on future net losses.
• HHS Proposal Status: Track the outcome of the HHS RFP submission, as funding here is critical to offsetting the projected cash burn in late 2006.